면역요법

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (새로운 창 열기)

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS

Source‎: N Engl J Med 2017;376(9):836-47.

Indexed‎: PubMed 28249141

DOI‎: 10.1056/NEJMoa1609783

https://www.ncbi.nlm.nih.gov/pubmed/28249141 (새로운 창 열기)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (새로운 창 열기)

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA

Source‎: N Engl J Med 2014;371(16):1507-17.

Indexed‎: PubMed 25317870

DOI‎: 10.1056/NEJMoa1407222

https://www.ncbi.nlm.nih.gov/pubmed/25317870 (새로운 창 열기)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (새로운 창 열기)

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA

Source‎: N Engl J Med 2018;378(5):439-48.

Indexed‎: PubMed 29385370

DOI‎: 10.1056/NEJMoa1709866

https://www.ncbi.nlm.nih.gov/pubmed/29385370 (새로운 창 열기)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (새로운 창 열기)

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE

Source‎: Cancer 2013;119(22):4036-43.

Indexed‎: PubMed 24006085

DOI‎: 10.1002/cncr.28334

https://www.ncbi.nlm.nih.gov/pubmed/24006085 (새로운 창 열기)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (새로운 창 열기)

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S

Source‎: Clin Cancer Res 2016;22(8):1951-7.

Indexed‎: PubMed 26644412

DOI‎: 10.1158/1078-0432.CCR-15-1349

https://www.ncbi.nlm.nih.gov/pubmed/26644412 (새로운 창 열기)

종양학과(소아청소년과)

면역요법

한국어

면역요법

https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (새로운 창 열기)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (새로운 창 열기)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (새로운 창 열기)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (새로운 창 열기)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (새로운 창 열기)

병원 교섭 위원회(HLC)

의학 자료집

동영상

면역요법

언어를 선택하세요

공유